GSK lifts annual forecasts again, powered by strong vaccine launch
By Eva Mathews (Reuters) -GSK raised its full-year profit and sales forecasts for a second time on Wednesday, following the strong launch of its ...
Stay updated with breaking news from Eva Mathews. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
By Eva Mathews (Reuters) -GSK raised its full-year profit and sales forecasts for a second time on Wednesday, following the strong launch of its ...
(Reuters) - Britain's medicines regulator on Wednesday approved Pfizer Inc's drug to treat hair loss caused by an autoimmune disease. The drug, brande...
TP ICAP, the world's biggest inter-dealer broker, reported a 5% rise in third-quarter revenue on Tuesday, as a strong performance in its energy and commodities division helped offset weakness in its...
JNJ-3989 was initially developed by Arrowhead Pharmaceuticals and licensed to Johnson & Johnson-owned Janssen in 2018. Exclusive rights to the therapy will fuel the expansion of GSK's own hepatitis B treatment, bepirovirsen, which is currently in late-stage development, the company said. Hepatitis B, which affects an estimated 300 million people, is a life-threatening viral infection that attacks the liver and patients risk death from cirrhosis and liver cancer.
British drugmaker GSK said on Monday its cancer drug Jemperli met the primary goal of overall survival in patients with primary advanced or recurrent endometrial cancer in a late-stage trial. ...